Novartis

Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels[1] Signifor LAR, a next-generation somatostatin analog, provides a new option for patients with acromegaly with inadequately controlled disease[2] Signifor LAR FDA approval is … Read the full press release →

Leicester, UK, 15-12-2014 — /EuropaWire/ — A team from the University of Leicester and Leicester’s Hospitals has played a vital role in identifying a new treatment for reducing the risk of death or emergency hospital admission among patients with serious … Read the full press release →

Pivotal PIONEER study compared safety and efficacy of the two compounds in the prevention of neutropenia in patients with breast cancer PIONEER data supported filing for biosimilar filgrastim in the US The abstract of the study results is published online … Read the full press release →

Acromegaly is a rare pituitary disorder, which requires normalization of hormonal levels to help prevent the serious consequences of the disease[1],[2],[3],[4] Approval based on two large phase III trials showing superior efficacy of new formulation of Signifor over current SSAs … Read the full press release →

CSL to acquire Novartis influenza vaccines business, including development pipeline, for USD 275 million Announcement follows a transaction announced on April 22, 2014 to divest the non-influenza segments of Novartis Vaccines to GlaxoSmithKline Basel, Switzerland, 28-10-2014 — /EuropaWire/ — Novartis today … Read the full press release →

Secukinumab met primary and key secondary endpoints in two pivotal Phase III studies showing superiority to placebo in patients with adult onset psoriatic arthritis (PsA) PsA is a debilitating, long-lasting condition that causes inflammation of joints and skin and affects … Read the full press release →

KAE609 is the first antimalarial drug candidate with a novel mechanism of action to achieve positive clinical proof-of-concept in over 20 years KAE609 was tested in adult patients with uncomplicated malaria and showed a median parasite clearance time of 12 … Read the full press release →

Novartis acquires exclusive ex-US rights to Fovista from Ophthotech; upfront payment of USD 200 million plus potential future recruitment and other milestone payments; additionally Ophthotech to receive royalties on ex-US Fovista sales Fovista is the most advanced anti-PDGF technology in … Read the full press release →

Munich, Germany, 28-3-2014 — /EuropaWire/ — Sandoz announced today that Vasant (Vas) Narasimhan, MD, MPP, has been appointed Head of Sandoz Biopharmaceuticals & Oncology Injectables effective April 1, 2014. Vas, currently Global Head of Development at Novartis Vaccines, succeeds Ameet Mallik who will … Read the full press release →

Company is pleased to host second international conference dedicated to the research of rare and orphan diseases Novartis is engaging in public dialogue to help raise greater awareness of rare diseases and support for patients Company celebrates more than 50 … Read the full press release →

Novartis announces that researchers can now request access to patient level data on newly approved innovative medicines in the United States and EU in 2014 through the Idea Point portal, and is committed to enhancing Clinical Study Report summaries for … Read the full press release →

Shareholders approve 17th consecutive dividend increase to CHF 2.45 (+7%) per share for 2013, representing a payout of approximately 74% of net income from continuing operations Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors … Read the full press release →

FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is licensed in Europe, Australia and Canada Novartis is pursuing a US license that would allow immediate public health response to … Read the full press release →

Holzkirchen, Germany, 31-1-2014 — /EuropaWire/ — Sandoz announced today it has received Romanian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD. The product was first approved in Denmark on December 18th, 2013. The new product … Read the full press release →

Top global business school names thought leaders to Dean’s office; Deans, Professors and Directors will work alongside Dean Ilian Mihov to advance school’s mission Fontainebleau, France, Singapore, Abu Dhabi, 27-1-2014 — /EuropaWire/ — INSEAD, the leading international business school, announces the establishment … Read the full press release →

New report finds that a shift towards a circular economy can generate US$ 500 million in material cost savings, 100,000 new jobs and prevent 100 million tonnes of waste globally within five years Project Mainstream initiative aims to accelerate cross-sector engagement … Read the full press release →

General consensus that prohibitionist drugs policies have been largely unsuccessful Leaders debated the pace and direction of change in drugs policies The theme of the 44th World Economic Forum Annual Meeting is The Reshaping of the World: Consequences for Society, Politics and Business … Read the full press release →

Iran seeks to become one of the world’s top 10 economies in the future The international community needs to work together to help Syria President expects to conclude a comprehensive nuclear agreement The theme of the 44th World Economic Forum Annual … Read the full press release →

Open Forum Davos 2014 programme offers sessions on geopolitics, the economy, social affairs and more Panellists include top leaders from business, politics and civil society For more information about the 12th Open Forum, visit: http://www.openforumdavos.ch Davos, Switzerland, 20-1-2014 — /EuropaWire/ — On the … Read the full press release →